0000000000361905

AUTHOR

Kebede Hussein

showing 4 related works from this author

Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelof…

2010

The International Prognostic Scoring System (IPSS) and karyotype are useful tools for risk stratification in primary myelofibrosis (PMF). We examined the additional prognostic impact of red blood cell transfusion need among 254 consecutive patients (median age, 59 years). Sixty-two patients ( approximately 24%) required transfusions at diagnosis whereas 22 ( approximately 9%) became transfusion-dependent and 170 remained transfusion-independent during the first year postdiagnosis; after a median follow-up of 55 months, the respective median survivals were 35, 25, and 117 months (P < 0.01). Multivariable analysis confirmed the IPSS- and karyotype-independent prognostic weight of transfusion …

AdultMalemedicine.medical_specialtytransfusion myelofibrosisPROGNOSISmedicine.medical_treatmentmyelofibrosisHematopoietic stem cell transplantationSeverity of Illness IndexSettore MED/15 - Malattie Del SangueRisk FactorsInternal medicineSeverity of illnessmedicineHumansMyelofibrosisSurvival analysisAgedRetrospective StudiesAged 80 and overChromosome AberrationsHematologybusiness.industryPatient SelectionMyelodysplastic syndromesHematopoietic Stem Cell TransplantationRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryPrimary MyelofibrosisInternational Prognostic Scoring SystemRBC transfusiion; myelofibrosis; PROGNOSISFemaleErythrocyte TransfusionbusinessFollow-Up StudiesRBC transfusiionAmerican Journal of Hematology
researchProduct

Transfusion Need at Diagnosis or Its Development During the First Year of Diagnosis in Primary Myelofibrosis: Effect On Survival and Correlation with…

2009

Abstract Abstract 1909 Poster Board I-932 Background: The International Prognostic Scoring System (IPSS) for primary myelofibrosis (PMF) utilizes five independent predictors of inferior survival; of these, a hemoglobin level &lt;10 g/dL has the highest impact on survival (Cervantes et al. Blood 2009;113:2895). In the current study, we examined the additional prognostic impact of transfusion need at diagnosis or becoming transfusion-dependent in the first year of diagnosis. These events were also correlated with JAK2 or TET2 mutational status. Methods: Patients were selected from the Mayo Clinic PMF database based on availability of bone marrow histology and IPSS-relevant information at diag…

medicine.medical_specialtyBlood transfusionbusiness.industryProportional hazards modelmedicine.medical_treatmentImmunologymyelofibrosisTransfusion HistoryCell BiologyHematologyBiochemistrySettore MED/15 - Malattie Del SangueSurgeryTransplantationLog-rank testInternational Prognostic Scoring SystemInternal medicineCohortmedicinebusinessSurvival analysisBlood
researchProduct

Mature Survival Data for 176 Patients Younger Than 60 Years With Primary Myelofibrosis Diagnosed Between 1976 and 2005: Evidence for Survival Gains i…

2009

In the past 20 years, management of primary myelofibrosis (PMF) has incorporated new treatment approaches, but survival benefits have not been confirmed in controlled studies. This retrospective study includes 176 consecutive patients younger than age 60 years in whom PMF was diagnosed during a 30-year period (1976-2005). Median age at diagnosis was 50 years (range, 18-59 years), and 98 patients (55%) were men. At the time of this report, 99 patients (56%) had died; the 77 surviving patients were followed up for a median of 8 years (range, 4-24 years). Overall median survival was 9.2 years, and 15- and 20-year survival rates were 32% and 20%, respectively. According to the Dupriez Prognosti…

AdultMalemedicine.medical_specialtyMultivariate analysisTransplantation ConditioningAdolescentmedicine.medical_treatmentDiseaseHematopoietic stem cell transplantationKaplan-Meier EstimateDisease-Free SurvivalSettore MED/15 - Malattie Del Sanguemyelofibrosis survivalSurvival dataInternal medicinemedicineHumansMyelofibrosisSurvival rateProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelBrief ReportHematopoietic Stem Cell TransplantationRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyUnited StatesSurgerySurvival RatePrimary MyelofibrosisMultivariate AnalysisFemalebusiness
researchProduct

Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations.

2009

Chromosome 1 is the largest human chromosome and contains over 1600 known genes and 1000 novel coding sequences or transcripts. It is, therefore, not surprising that recurrent chromosome 1 abnormalities are regularly encountered in both neoplastic and non-neoplastic medical conditions. The current review is focused on myeloid malignancies where we summarize the relevant published literature and discuss specific karyotype-phenotype associations. We show that chromosome 1 abnormalities are most frequent in BCR-ABL-negative classic myeloproliferative neoplasms (MPN): polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Specific abnormalities include duplicat…

MyeloidChromosomal translocationBiologyTranslocation GeneticSettore MED/15 - Malattie Del Sanguehemic and lymphatic diseasesmedicineHumansGenes Tumor SuppressorMyelofibrosisGeneticsChromosome AberrationsMyeloproliferative DisordersEssential thrombocythemiaMyelodysplastic syndromesMyeloid leukemiaKaryotypeHematologyGeneral MedicineOncogenesmedicine.diseasemedicine.anatomical_structurePhenotypeChromosomes Human Pair 1Leukemia MyeloidKaryotypingMyelodysplastic Syndromeschomosome 1 myeloid malignancyChromosome DeletionLiterature surveyEuropean journal of haematology
researchProduct